EGRX Sep 2022 50.000 put
| Previous close | 6.30 |
| Open | N/A |
| Bid | 4.50 |
| Ask | 7.50 |
| Strike | 50.00 |
| Expiry date | 2022-09-16 |
| Day's range | 6.30 - 6.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
- GlobeNewswire
Eagle Pharmaceuticals to Host Second Quarter 2022 Financial Results on August 9, 2022
WOODCLIFF LAKE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 second quarter financial results on Tuesday, August 9, 2022, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: DateTuesday, August 9, 2022Time8:30 a.m. ETToll free (U.S.)800-445-7795In
- Zacks
TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B
TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25 billion.
- GlobeNewswire
Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial
WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the appointment of Debra M. Hussain as Senior Vice President, Head of Commercial. “We are very pleased with our acquisition of Acacia Pharma Group Plc (“Acacia”) and its two commercial products, BARHEMSYS® and BYFAVO®. As we commenced their integration, we continued to be impressed with Acacia Pharma’s previous plans and positioning of the products. It is
